• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Noxopharm’s Veyonda prevents cytokine storm in Covid-19 trial pharmaceutical-technology
    April 26, 2021
    Australian company Noxopharm has reported interim data from its NOXCOVID trial, which showed that its drug candidate Veyonda provided protection against hyper-inflammation (cytokine storm) in moderate Covid-19 patients.
  • Noxopharm Files Septic Shock Treatment Patent for Veyonda® americanpharmaceuticalreview
    April 15, 2021
    Australian clinical-stage drug development company Noxopharm Limited announced an international patent application aimed at protecting the use of experimental anti-cancer drug, Veyonda® (idronoxil), in blocking the development of septic shock ...
  • Noxopharm reports Covid-19 trial programme to commence in Europe pharmaceutical-business-review
    July 01, 2020
    Noxopharm, a clinical-stage Australian drug development company, has announced commencement of its NOXCOVID clinical program with a planned Phase I trial in Europe.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service